If you want to search for other Sectors or other Countries, you can check them out here:
Stock investments ranging from Biotech, Pharmaceutical, and Medical Devices in the Healthcare Sector. Covering Clinical Trial recommendations and FDA Approvals.
7/26/13
4 Best Biopharma Stock Trades 2013
Below are some of the best trades in the Biopharma Stock Sector since January 2013. I have gathered my research from a pretty good stock investment forum, 4-Trader. It's all free. I would never ask you to pay for anything on my site. No catches, no gimmicks.
If you want to search for other Sectors or other Countries, you can check them out here:
If you want to search for other Sectors or other Countries, you can check them out here:
6/7/13
Antares Pharma: $ATRS A Risky Buy
Antares Pharmaceuticals is a Hot Biopharma Investment Right Now
So let's start off with Antares Pharma. Most of my previous stocks that I have written about have done very well in the past few years so I'll continue with that trend with this stock: ATRS.
ATRS FDA Approval PDUFA Date is Oct. 14th
Antares PharmaHere's a few web links to help you out on Antares and what they are all about.
- From MarketWatch: ATRS Antares Pharma
- From Yahoo Finance: Big News with Antares Pharma Welcomes Marvin Samson to Board of Directors, from Global Manufacturing Leader, TEVA
- From Morningstar, their analysis of Antares Stock ATRS
- From Seeking Alpha: 4 Top Small Cap Biotech Acquisition Targets: Trius, Antares, Acadia, AcelRx Pharmaceuticals
- From Investor's Hub: ATRS
This is what that blogger from Seeking Alpha, Scott Matusow has to say about Antares. I agree with a commenter that a buyout would be a couple of years down the road.
Antares Pharma (ATRS)
Labels:
$ATRS,
Antares,
antares pharma,
antares pharmaceuticals,
antares stock,
antares stock quote,
atrs,
atrs stock quote,
biopharma,
due diligence,
good buy,
investment,
investor,
Seeking Alpha,
stock buy,
twitter
4/16/12
Biopharma Investor
We are working on creating a new full feature design for BioPharma Investor here soon. Hopefully a better website and more updated content. Thanks for your patience while I get this up and running. Web Design and Database Programming doesn't happen overnight.
7/8/11
60 Minutes on J. Craig Venter: Designing Life
June 12, 2011 5:00 PM
Steve Kroft profiles famous microbiologist J. Craig Venter, whose scientists have already mapped the human genome and created what he calls "the first synthetic species."
Read more: http://www.cbsnews.com/video/watch/?id=7369820n&tag=cbsnewsMainColumnArea.8#ixzz1RZ052a3e
(CBS News)
This story was first published on Nov. 21, 2010. It was updated on June 12, 2011.
For generations, scientists have wrestled with the idea of creating new forms of life in the laboratory. Now that age is upon us.
Watch the Segment »
Labels:
60 Minutes,
Artificial gene synthesis,
CBS,
Celera Genomics,
Craig Venter,
DNA,
Human Genome Project,
J. Craig Venter Institute,
Steve Kroft,
Synthetic Biology
6/30/11
Cancer Clinical Trials and Treatments Late Stage Developments
For the cancer drug research enthusiast, this report might read in places like a special oncology edition of a gun magazine. Indeed, there are plenty of weapons against cancer to read about here. Several of the drugs listed here represent the advancement of relatively new methods of attacking cancer, including "armed antibodies" and cancer-killing viruses.
In addition, decades of basic research into the molecular drivers of cancer growth are bearing fruit for drug developers. Not only are these companies making progress in clinical trials, they have landed buyout deals and lucrative partnerships. It's also clear that relatively small companies like Aveo Pharmaceuticals and Curis are making inroads along side the big boys like Pfizer and Roche.
There are 10 late-stage drugs listed in this report, but this editor hesitates to call them the "Top 10" only because there are so many variables to consider to rank them in such a way objectively. Yet these 10 drugs have certainly been generating news and, in most cases, lots of interest among investors and the medical community. All of the drugs have reached pivotal trials for at least one type of cancer.
Here's the list in alphabetical order by each drug's most commonly used moniker, whether that is its alphanumeric code name or generic name. As always, please let us know whether you think there are cancer drugs in pivotal trials that you think should have been on this list or ones on this list that shouldn't be.
1. Carfilzomib - multiple myeloma
2. Crizotinib (PF-02341066) - lung cancer
3. GDC-0449 (vismodegib) - basal cell carcinoma
4. OncoVex - advanced melanoma
5. PLX4032 (RG7204) - melanoma
6. Ponatinib - leukemia
7. SGN-35 (brentuximab vedotin) - Hodgkin's lymphoma, anaplastic large cell lymphomas
8. Tivozanib (AV-951) - advanced renal cell carcinoma
9. T-DM1 (Trastuzumab-DM1) - breast cancer
10. XL184 (cabozantinib) - prostate cancer
Labels:
Amgen,
Ariad Pharmaceutical,
Bristol-Meyers,
cancer,
Cancer Treatments,
chemotherapy,
Clinical Trials,
Curis,
Late Stage Cancer,
Onxy,
Pfizer,
Roche
Subscribe to:
Posts (Atom)

